The latest price in 2024 announced: Capmatinib’s new weapon against lung cancer!

Capmatinib is a targeted therapy for non-small cell lung cancer (NSCLC). Its unique mechanism of action makes it an important treatment option for specific patient groups. The development and launch of this drug represents continuous progress in the medical field in cancer treatment.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

Capmatinib is mainly used for patients with MET (tyrosine kinase) gene abnormalities. MET is a protein that is involved in the regulation of life activities such as cell growth, differentiation and migration. In some cancers, abnormal activation of the MET pathway may lead to uncontrolled proliferation and spread of cancer cells. The mechanism of action of capmatinib is to selectively inhibit the activity of MET kinase, thereby blocking abnormal cell signaling and preventing normal growth of cancer cells.

As an oral drug, capmatinib is relatively convenient to use, and its unique targeted treatment mechanism makes it different from traditional chemotherapy and radiotherapy methods. This provides a new, more personalized treatment option for patients who are resistant or intolerant to traditional treatments.

Clinical trials and studies have shown that capmatinib shows promising efficacy in patients with MET driven non-small cell lung cancer. However, like all drugs, capmatinib may be associated with some side effects, including but not limited to fatigue, nausea, vomiting, etc. Therefore, during the use of capmatinib, patients need to pay close attention to their physical condition and promptly report any symptoms of discomfort to their doctor.